SCHEMBL23527331

SCHEMBL23527331

CC(=O)OC1CN(C(=O)O)CCC1Oc1cccc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.46
UBE2M P61081 2/20 0.44
DCUN1D1 Q96GG9 2/20 0.44
MEN1 O00255 2/20 0.41
KMT2A Q03164 1/20 0.41
ABHD6 Q9BV23 2/20 0.40
MGLL Q99685 1/20 0.40
NOTUM Q6P988 1/20 0.40
TP53 P04637 1/20 0.40
TRPA1 O75762 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
CNR1 P21554 1/20 0.39
ACACB O00763 1/20 0.38
FFAR1 O14842 1/20 0.38
ENPP2 Q13822 1/20 0.38
PSEN1 P49768 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23600182 0.88 USP30 (0.44) EPHX2UBE2MDCUN1D1MEN1KMT2A
SCHEMBL23526899 0.88 USP30 (0.44) EPHX2UBE2MDCUN1D1MEN1KMT2A
SCHEMBL30900988 0.80 TACR1 (0.43) EPHX2MEN1KMT2AABHD6MGLL
SCHEMBL23526875 0.80 TACR1 (0.43) EPHX2MEN1KMT2AABHD6MGLL
SCHEMBL9903075 0.78 EPHX2 (0.65) EPHX2MEN1KMT2AABHD6MGLL
SCHEMBL23526901 0.78 EPHX2 (0.40) EPHX2UBE2MDCUN1D1MEN1KMT2A
SCHEMBL23527274 0.77 USP30 (0.46) EPHX2UBE2MDCUN1D1MEN1KMT2A
SCHEMBL23564407 0.77 SLC6A2 (0.44) EPHX2UBE2MDCUN1D1MEN1KMT2A
SCHEMBL12184249 0.75 EPHX2 (0.56) EPHX2MEN1KMT2AABHD6MGLL
SCHEMBL23564392 0.75 USP30 (0.46) EPHX2UBE2MDCUN1D1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081523-B1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2024-12-25 EP disclosed
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-23 US disclosed
WO-2021133750-A1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-01 WO disclosed
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKA, DGKZ, DGKK EPHX2 3656/4885UBE2M 4633/4885DCUN1D1 816/4885
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators DGKA, DGKZ, DGKK EPHX2 3656/4885UBE2M 4633/4885DCUN1D1 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.